Amarin Corporation plc
Reports in 2d· 2026-04-29
-11.2% · 90d
$13.93
-0.38 (-2.66%)
After-Hours $14.28(+0.35)
News
(2)April 2026
AMARIN CORP PLC\UK — DEF 14A Filing
AMRNAMARIN CORP PLC\UK
# 🧾 What This Document Is This is a **Definitive Proxy Statement (DEF 14A)**. Think of it as an invitation and information packet for Amarin's shareholders. It's sent ahead of the **Annual General Meeting (AGM)** scheduled for **May 13, 2026**, to explain what will be voted on and provide key comp
Read summaryView on SEC EDGAR
March 2026
AMARIN CORP PLC\UK — PRE 14A Filing
AMRNAMARIN CORP PLC\UK
# 🧾 What This Document Is This is a **PRELIMINARY proxy statement** (form PRE 14A) for **Amarin Corporation plc**. It's a formal notice and information packet sent to shareholders ahead of the company's **2026 Annual General Meeting**. Think of it as the agenda and instruction manual for a company'
Read summaryView on SEC EDGAR
Peers in Drug Manufacturers - General
LLY#1
Eli Lilly and Company
$854.72B+0.20%
JNJ#2
Johnson & Johnson
$581.22B
ABBV#3
AbbVie Inc.
$375.69B+0.38%
AZN#4
AstraZeneca PLC
$318.03B+0.35%
MRK#5
Merck & Co., Inc.
$303.00B-0.41%
NVS#6
Novartis AG
$295.06B+0.41%
AMGN#7
Amgen Inc.
$191.91B+1.66%
GILD#8
Gilead Sciences, Inc.
$176.37B+0.39%
NVO#9
Novo Nordisk A/S
$165.39B-0.45%
PFE#10
Pfizer Inc.
$154.84B-0.91%